UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012

SANOFI INDIA LIMITED

Registered Office : 54/A, Sir Mathuradas Vasanji Road, Andheri East, Mumbai 400 093

Part I

(Rs. Million)

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
1. Income from Operation s						
(a) Net Sales (net of excise duty)	3,741	3,225	3,028	6,966	5,791	12,297
(b) Other Operating Income Total	185 3,926	203 3,428	195 3,223	388 7,354	374 6,165	753 13,050

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
income from Operation s (net)						
2 Expendit ure						
(a) Cost of Materials Consume d	1,428	1,322	1,315	2,750	2,507	4,916
(b) Purchase of stock in trade	521	478	490	999	726	1,353
(c) Changes in inventori es of finished goods, work in progress and stock	(98)	(215)	(299)	(313)	(366)	(76)

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
in trade						
(d) Employee benefits expense	548	490	441	1,038	846	1,764
(e) Depreciat ion and amortisat ion expense	186	183	54	369	108	311
(f) Other expenses	820	658	653	1,478	1,215	2,579
(g) Total Expenses	3,405	2,916	2,654	6,321	5,036	10,847
3 Profit from Operation s before other income and finance costs (1- 2)	521	512	569	1,033	1,129	2,203

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
4 Other Income	82	86	166	168	364	641
5 Profit before finance costs (3+4)	603	598	735	1,201	1,493	2,844
6 Finance costs	4	4	-	8	-	4
7 Profit before tax and Exception al items (5-6)	599	594	735	1,193	1,493	2,840
8 Tax Expense	194	193	238	387	490	928
9 Net Profit for the period before Exception al items (7-8)	405	401	497	806	1,003	1,912

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
10 Exception al item (net of tax)	-	-	-	-	-	-
11 Net Profit for the period after Exception al items (9+10)	405	401	497	806	1,003	1,912
12 Paid- up equity share capital (Face Value of Rs. 10 per Share)	230	230	230	230	230	230
13 Reserves excluding Revaluati on						10,781

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
Reserves as per balance, sheet of previous accountin g year						
14 Earnings Per Share (EPS) before Exception al items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	17.61	17.43	21.61	35.04	43.61	83.13
15	17.61	17.43	21.61	35.04	43.61	83.13

Particul ars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
Earnings						
Per Share						
(EPS)						
after						
Exception						
al items						
(Rs.)						
(Basic						
and						
diluted						
EPS for						
the						
period,						
for the						
year to						
date and						
for the						
previous						
year)						Top of page

Top of page

Part II

Particulars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
-------------	---	---	---	--	--	--

A. PARTICULA RS OF SHAREHOL DING						
1 Public Shareholding						
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%	39.60%
2 Promoters and Promoter group Shareholding						
a) Pledged/Encu mbered						
- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total	NIL	NIL	NIL	NIL	NIL	NIL

Particulars	Quarter ended 30.06.2 012 Unaudite d	Quarter ended 31.03.2 012 Unaudite d	Quarter ended 30.06.2 011 Unaudite d	Half Year ended 30.06.2 012 Unaudite d	Half Year ended 30.06.2 011 Unaudite d	Year ended 31.12.2 011 (Audited)
A. PARTICULA RS OF SHAREHOL DING						
share capital of the company)						
b) Non- encumbered						
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587
 Percentage of shares (as a % of total shareholding of promoter and promoter group) 	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%	60.40%	60.40% Top of page

Particulars	3 Months ended June 30,2012
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	32
Disposed of during the quarter	32
Remaining unresolved at the end of the quarter	NIL

Top of page

The Statement of Assets and Liabilities as required under clause 41(V)(h) of the Listing Agreement is as under:

Particulars	As at June 30, 2012 Unaudited	As at Dec 31, 2011 Audited
EQUITY AND LIABILITIES :		
Shareholders' funds :		
(a) Share capital	230	230
(b) Reserves & Surplus *	11,631	10,936
Sub-total - Shareholder's Funds	11,861	11,166
Non-current liabilities		
(a) Other long term liabilities	10	10
(b) Long term provisions	362	313
(c) Deferred Tax Liabilities (Net)	88	85
Sub-total - Non-current liabilities	460	408

Particulars	As at June 30, 2012 Unaudited	As at Dec 31, 2011 Audited
Current liabilities		
(a) Trade Payables	1,459	1,435
(b) Other current liabilities	656	750
(c) Short-term provisions	628	1,266
Sub-total - Current liabilities	2,743	3,451
TOTAL EQUITY & LIABILITIES	15,064	15,025
ASSETS		
Non-current assets		
(a) Fixed Assets (Including Capital Work in Progress)	7,548	7,598
(b) Non current investments	4	4
(c) Long term loans and advances	599	771
(d) Other non-current assets	13	6
Sub-Total - Non Current Assets	8,164	8,379
Current assets		
(a) Inventories	2,996	2,543
(b) Trade receivables	1,258	1,040
(c) Cash & Bank Balances	2,345	2,342
(d) Short term loans & advances	239	657
(e) Other current assets	62	64

Particulars	As at June 30, 2012 Unaudited	As at Dec 31, 2011 Audited
Sub-total - Current assets	6,900	6,646
TOTAL ASSETS	15,064	15,025

* After considering Interim Dividend

Top of page

Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on July 25, 2012.
- 2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended June 30, 2012.
- The Registrar of Companies, Maharashtra approved change of name of the Company from Aventis Pharma Limited to Sanofi India Limited, with effect from May 11, 2012 pursuant to the resolution passed by the Members at the Annual General Meeting held on May 3, 2012.
- 4. The Board of Directors has declared an Interim Dividend of Rs. 4 per Equity share of Rs. 10 to be paid to those Members whose names appear on the Register of Members of the Company on August 3, 2012 being the Record Date. The said dividend will be paid on August 16, 2012.
- 5. The profit for the quarter and half year ended June 30, 2012 has been impacted due to the amortization costs relating to the brands and technical know-how acquired in 2011 from Universal Medicare Private Limited and lower interest income as a result of the above investment.
- 6. The Company has a single business segment namely 'Pharmaceutical Business'.
- 7. The figures for the previous periods have been re-grouped, wherever necessary.

SANOFI INDIA LIMITED DR. SHAILESH AYYANGAR MANAGING DIRECTOR